DE69318902D1 - Rapamycin zur Behandlung von Morbus Crohn, ulcerativer Colitis und ulcerative Proctitis - Google Patents

Rapamycin zur Behandlung von Morbus Crohn, ulcerativer Colitis und ulcerative Proctitis

Info

Publication number
DE69318902D1
DE69318902D1 DE69318902T DE69318902T DE69318902D1 DE 69318902 D1 DE69318902 D1 DE 69318902D1 DE 69318902 T DE69318902 T DE 69318902T DE 69318902 T DE69318902 T DE 69318902T DE 69318902 D1 DE69318902 D1 DE 69318902D1
Authority
DE
Germany
Prior art keywords
ulcerative
rapamycin
crohn
disease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69318902T
Other languages
English (en)
Other versions
DE69318902T2 (de
Inventor
Craig Eugene Caufield
John Henry Musser
Surendra Nath Sehgal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of DE69318902D1 publication Critical patent/DE69318902D1/de
Publication of DE69318902T2 publication Critical patent/DE69318902T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69318902T 1992-08-17 1993-08-06 Rapamycin zur Behandlung von Morbus Crohn, ulcerativer Colitis und ulcerative Proctitis Expired - Fee Related DE69318902T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/931,243 US5286731A (en) 1991-09-17 1992-08-17 Method of treating immunoinflammatory bowel disease

Publications (2)

Publication Number Publication Date
DE69318902D1 true DE69318902D1 (de) 1998-07-09
DE69318902T2 DE69318902T2 (de) 1999-02-25

Family

ID=25460461

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69318902T Expired - Fee Related DE69318902T2 (de) 1992-08-17 1993-08-06 Rapamycin zur Behandlung von Morbus Crohn, ulcerativer Colitis und ulcerative Proctitis

Country Status (13)

Country Link
US (1) US5286731A (de)
EP (1) EP0583925B1 (de)
JP (1) JP2637682B2 (de)
KR (1) KR100299395B1 (de)
AT (1) ATE166786T1 (de)
AU (1) AU677011B2 (de)
CA (1) CA2104042A1 (de)
DE (1) DE69318902T2 (de)
DK (1) DK0583925T3 (de)
ES (1) ES2116415T3 (de)
GR (1) GR3027610T3 (de)
HK (1) HK1009641A1 (de)
SG (1) SG47786A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US6204243B1 (en) 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5525610A (en) * 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
US20040018236A1 (en) * 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
DK0956034T3 (da) 1996-07-30 2002-12-16 Novartis Ag Farmaceutiske præparater til behandling af transplantatafstødning, autoimmune eller inflammatoriske tilstande omfattende cyclosporin A og 40-O-(2-hydroxyethyl)-rapamycin
IT1289815B1 (it) * 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
US6670355B2 (en) * 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
MXPA03002258A (es) 2000-09-19 2003-06-24 Wyeth Corp Esteres de rapamicina solubles en agua.
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
ATE477804T1 (de) * 2001-03-15 2010-09-15 Soligenix Inc Verfahren zur behandlung von entzündlichen erkrankungen des verdauungstrakts mit topisch wirksamen kortikosteroiden
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
BR0211986A (pt) 2001-08-22 2004-09-28 Wyeth Corp 29-enóis de rapamicina
CA2455311A1 (en) 2001-08-22 2003-03-06 Wyeth Rapamycin dialdehydes
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
BR0313024A (pt) 2002-07-30 2005-07-12 Wyeth Corp Formulações parenterais contendo um hidroxiéster de rapamicina
CA2496332A1 (en) * 2002-09-17 2004-04-01 Wyeth Oral formulations
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
BRPI0409632A (pt) * 2003-04-22 2006-04-25 Wyeth Corp combinações antineoplásticas
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US7135455B2 (en) * 2004-11-15 2006-11-14 Allergan, Inc Methods for the therapeutic use of cyclosporine components
US7151085B2 (en) * 2004-11-15 2006-12-19 Allergan, Inc. Therapeutic methods using cyclosporine components
CA2629714A1 (en) 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of an mtor inhibitor to treat patients with cancer
US20100081681A1 (en) * 2006-08-16 2010-04-01 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
US7867988B2 (en) 2006-09-13 2011-01-11 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
KR20110074758A (ko) * 2008-10-03 2011-07-01 엘릭서 메디컬 코포레이션 마크로사이클릭 락톤 화합물 및 이를 사용하는 방법
CA2937492C (en) 2008-11-11 2019-08-13 The Board Of Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
BRPI1010655A2 (pt) 2009-04-10 2019-09-03 Qi Haiyan novos agentes antienvelhecimento e métodos para identificá-los
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US20110150856A1 (en) * 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
PH26083A (en) * 1987-11-09 1992-02-06 Sandoz Ltd 11, 28-dioxa-4-azatricyclo [22.3.1.04.9) octacos-18-ene derivatives and pharmaceutical compositions containing them and method of use thereof
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5023264A (en) * 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) * 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
EP0542860B1 (de) * 1990-08-10 1998-05-20 AnorMED Inc Immunosuppressive zusammensetzungen
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5091389A (en) * 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
US5138051A (en) * 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
US5102876A (en) * 1991-05-07 1992-04-07 American Home Products Corporation Reduction products of rapamycin
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease

Also Published As

Publication number Publication date
DK0583925T3 (da) 1998-10-12
EP0583925A1 (de) 1994-02-23
KR100299395B1 (ko) 2001-10-22
SG47786A1 (en) 1998-04-17
JPH06183967A (ja) 1994-07-05
AU4465493A (en) 1994-02-24
KR940003555A (ko) 1994-03-12
ATE166786T1 (de) 1998-06-15
ES2116415T3 (es) 1998-07-16
EP0583925B1 (de) 1998-06-03
JP2637682B2 (ja) 1997-08-06
GR3027610T3 (en) 1998-11-30
AU677011B2 (en) 1997-04-10
HK1009641A1 (en) 1999-06-04
DE69318902T2 (de) 1999-02-25
CA2104042A1 (en) 1994-02-18
US5286731A (en) 1994-02-15

Similar Documents

Publication Publication Date Title
ATE166786T1 (de) Rapamycin zur behandlung von morbus crohn, ulcerativer colitis und ulcerative proctitis
ATE135226T1 (de) Zusammensetzung enthaltend heparin und rapamycin
ATE187889T1 (de) Vorbeugung und behandlung der peripheren neuropathie
ES2095926T5 (es) Cyclosporins.
DE69429369D1 (de) Verfahren und mittel zur behandlung abnormaler zustände des epitheliums von körperöffnungen
SG47639A1 (en) Method of treating hyperproliferative vascular disease
DE59508815D1 (de) Vorrichtung zum durchströmenden Behandeln von Textilgut od. Dgl.
DE59100861D1 (de) Kontinue-verfahren zur behandlung von textilen warenbahnen und entsprechende anlage.
FI903775A0 (fi) Foerfarande foer behandling av skinn och de erhaollna skinnen.
DE69412178D1 (de) Apparat zur Behandlung von Lagen
DE69321893D1 (de) Verfahren zum Nachweis von Alzheimer-Krankheit
DE69001988D1 (de) Behandlung des schocks mit cyclodextrin und dessen derivaten.
RU93056862A (ru) Способ предотвращения рестеноза или снижения его степени
DE59509005D1 (de) Vorrichtung zum durchströmenden Behandeln von Textilgut od. dgl.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: WYETH (N.D.GES.D. STAATES DELAWARE), MADISON, N.J.

8339 Ceased/non-payment of the annual fee